Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer’s (HEART) Trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Research indicates that certain antihypertensive medications alter Alzheimer's disease (AD) biomarkers in Caucasians. The renin angiotensin system (RAS) regulates blood pressure (BP) in the body and the brain and may directly influence AD biomarkers, including amyloid-β (Aβ) neuropathology, cerebral blood flow (CBF), and inflammatory markers. This hypothesis is supported by studies, including ours, showing that antihypertensives targeting the RAS reduce the risk and slow the progression of AD in Caucasians. While mounting evidence supports a protective role of RAS medications in Caucasians, this mechanism has not been explored in African Americans. To assess the mechanism by which RAS medications modify the brain RAS, cerebrospinal fluid (CSF) Aβ, CBF, and inflammatory markers in African Americans, we are conducting an eight month, Phase Ib randomized, placebo controlled trial, enrolling 60 middle-aged (45-70 years), non-demented individuals, at risk for AD by virtue of a parental history. Participants include normotensive and treated hypertensives that have never been exposed to a RAS medication. Participants are randomized (1 : 1:1) by gender and BP medication use (yes/no) to one of three groups: placebo, or 20 mg, or 40 mg telmisartan (Micardis), to determine the dose required to penetrate the CNS. Our overarching hypothesis is that, compared to placebo, both doses of telmisartan will penetrate the CNS and produce salutary, dose dependent effects on the brain RAS as well as CSF Aβ, CBF, and CSF inflammatory markers in African Americans, over eight months. This manuscript describes the trial rationale and design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486
Davies, N. M., Kehoe, P. G., Ben-Shlomo, Y., & Martin, R. M. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110347 · Cited by 212 · cited 1×
“This hypothesis is supported by studies showing that antihypertensives targeting the RAS, that most commonly are angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (A2RBs), reduce the risk and slow the progression of clinical AD [6-8].”
Self-citationKehoe, P. G., Wong, S., AL Mulhim, N., Palmer, L. E., & Miners, J. S. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0217-7 · Cited by 203 · cited 3×
“Aβ1–42 levels will be determined using a sandwich ELISA (INNOTEST® β-AMYLOID(1–42), Innogenetics, Gent, Belgium), specifically constructed to measure Aβ containing both the first and 42nd amino acid [25].”
MethodSelf-citationPositive Aspects of Family Caregiving for Dementia: Differential Item Functioning by Race
Roth, D. L., Dilworth-Anderson, P., Huang, J., Gross, A. L., & Gitlin, L. N. (2015) · The Journals of Gerontology Series B: Psychological Sciences and Social Sciences · doi:10.1093/geronb/gbv034 · Cited by 144 · cited 1×
“Questionnaires include information pertaining to: 1) medical and medication history; 2) exercise [40]; 3) sleep [41]; 4) nutrition [42]; 5) positive [43, 44] and negative (stress) aspects of caregiving [45–47]; 6) depression [48]; and 7) behavior and quality of life of their parent with AD [49, 50].”
BackgroundDEVELOPMENT OF A SHORT FORM INVENTORY TO ASSESS GRIEF IN CAREGIVERS OF DEMENTIA PATIENTS
MARWIT, S. J., & MEUSER, T. M. (2005) · Death Studies · doi:10.1080/07481180590916335 · Cited by 130 · cited 1×
“Questionnaires include information pertaining to: (i) medical and medication history; (ii) exercise [40]; (iii) sleep [41]; (iv) nutrition [42]; (v) positive [43, 44] and negative (stress) aspects of caregiving [45-47]; (vi) depression [48]; and (vii) behavior and quality of life of their parent with AD [49, 50].”
Background
Cited by
Neurovascular and Cognitive Dysfunction in Hypertension: Epidemiology, Pathobiology, and Treatment
Iadecola, C., & Gottesman, R. F. (2019) · Circulation Research · doi:10.1161/circresaha.118.313260 · Cited by 502
Kehoe, P. G. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171119 · Cited by 133
Self-citationThe depressor axis of the renin–angiotensin system and brain disorders: a translational approach
Gironacci, M. M., Vicario, A., Cerezo, G., & Silva, M. G. (2018) · Clinical Science · doi:10.1042/cs20180189 · Cited by 60
Cunningham, E. L., Todd, S. A., Passmore, P., Bullock, R., & McGuinness, B. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004034.pub4 · Cited by 45
How ACE inhibitors transformed the renin–angiotensin system
Bakhle, Y. S. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15045 · Cited by 41
Metadata
- Authors
- Wharton, W., Goldstein, F. C., Tansey, M. G., Brown, A. L., Tharwani, S. D., Verble, D. D., Cintron, A., & Kehoe, P. G.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2017-12-19
- Volume
- 61
- Issue
- 2
- Pages
- 815-824
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2775061891
- Cited by
- 24
- References
- 5
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer’s (HEART) Trial. https://app.cochat.ai/papers/10.3233/jad-161198
- The paper
- Wharton, W., Goldstein, F. C., Tansey, M. G., Brown, A. L., Tharwani, S. D., Verble, D. D., Cintron, A., & Kehoe, P. G. (2017). Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer’s (HEART) Trial. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-161198
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.